The APOBEC-2 crystal structure and functional implications for the deaminase AID

Nature

Volumn 445, Issue 7126, 2007, Pages 447-451

  Prochnow, Courtney ^a   Bransteitter, Ronda ^a   Klein, Michael G ^a   Goodman, Myron F ^a   Chen, Xiaojiang S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATION INDUCED CYTIDINE DEAMINASE; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 2; DEAMINASE; POLYPEPTIDE; TETRAMER; UNCLASSIFIED DRUG;

ANTIBODY; CRYSTAL STRUCTURE; DNA; ENZYME; HOMOLOGY; MUTATION; PEPTIDE; RNA;

ALPHA HELIX; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DEAMINATION; ENZYME SUBSTRATE; FUNCTIONAL PROTEOMICS; HYPERIMMUNOGLOBULINEMIA M; MUTATION RATE; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY; STRUCTURAL PROTEOMICS;

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33846555779     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature05492     Document Type: Article

References (28)

1. Pham, P., Bransteitter, R. & Goodman, M. F. Reward versus risk: DNA cytidine deaminases triggering immunity and disease. Biochemistry 44, 2703-2715 (2005).
2. Conticello, S. G., Thomas, C. J. F., Petersen-Mahrt, S. K. & Neuberger, M. S. Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases. Mol. Biol. Evol. 22, 367-377 (2004).
3. Bransteitter, R., Sneeden, J. L., Allen, S., Pham, P. & Goodman, O. M. F. First AID (activation-induced cytidine deaminase) is needed to produce high affinity isotype-switched antibodies. J. Biol. Chem. 281, 16833-16836 (2006).
4. Chiu, Y. L. & Greene, W. C. Multifaceted antiviral actions of APOBEC3 cytidine deaminases. Trends Immunol. 27, 291-297 (2006).
5. Cullen, B. R. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J. Virol. 80, 1067-1076 (2006).
6. Franca, R., Spadari, S. & Maga, G. APOBEC deaminases as cellular antiviral factors: a novel natural host defense mechanism. Med. Sci. Monit. 12, RA92-RA98 (2006).
7. Bonvin, M. et al. Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 43, 1364-1374 (2006).
8. Johansson, E., Mejlhede, N., Neuhard, J. & Larsen, S. Crystal structure of the tetrameric cytidine deaminase from Bacillus subtilis at 2.0 Å resolution. Biochemistry 41, 2563-2570 (2002).
9. Xie, K. et al. The structure of a yeast RNA-editing deaminase provides insight into the fold and function of activation-induced deaminase and APOBEC-1. Proc. Natl Acad. Sci. USA 101, 8114-8119 (2004).
10. Teh, A. et al. The 1.48 Å resolution crystal structure of the homotetrameric cytidine deaminase from mouse. Biochemistry 45, 7825-7833 (2006).
11. Chung, S. J., Fromme, J. C. & Verdine, G. L. Structure of human cytidine deaminase bound to a potent inhibitor. J. Med. Chem. 48, 658-660 (2005).
12. Betts, L., Xiang, S., Short, S. A., Wolfenden, R. & Carter, C. W. Cytidine deaminase. The 2.3 Å crystal structure of an enzyme: transition-state analog complex. Curr. Biol. 235, 635-656 (1994).
13. Smith, A. A., Carlow, D. C., Wolfenden, R. & Short, S. A. Mutations affecting transition-state stabilization by residues coordinating zinc at the active site of cytidine deaminase. Biochemistry 33, 6468-6474 (1994).
14. Durandy, A., Peron, S. & Fischer, A. Hyper-IgM syndromes. Curr. Opin. Rheumatol. 18, 369-376 (2006).
15. Minegishi, Y. et al. Mutations in activation-induced cytidine deaminase in patients with hyper IgM syndrome. Clin. Immunol. 97, 203-210 (2000).
16. Anant, S. et al. ARCD-1, an apobec-1-related cytidine deaminase, exerts a dominant negative effect on C to U RNA editing. Am. J. Cell Physiol. 281, C1904-C1916 (2001).
17. Jarmuz, A. et al. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79, 285-296 (2002).
18. Shindo, K. et al. The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J. Biol. Chem. 278, 44412-44416 (2003).
19. Wiegand, H. L., Doehle, B. P., Bogerd, H. P. & Cullen, B. R. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J. 23, 2451-2458 (2004).
20. Opi, S. et al. Monomeric APOBEC3G is catalytically active and has antiviral activity. J. Virol. 80, 4673-4682 (2006).
21. Navarro, F. et al. Complementary function of the two catalytic domains of APOBEC3G. Virology 333, 374-386 (2005).
22. Wang, J. et al. Identification of a specific domain required for dimerization of activation-induced cytidine deaminase. J. Biol. Chem. (in the press).
23. Teng, B. et al. Mutational analysis of apolipoprotein B mRNA editing enzyme (APOBEC1): structure-function relationships of RNA editing and dimerization. J. Lipid Res. 40, 623-635 (1999).
24. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
25. Terwilliger, T. C. & Berendzen, J. Automated MAD and MIR structure solution. Acta Crystallogr. 55, 849-861 (1999).
26. Schneider, T. R. & Sheldrick, G. M. Substructure solution with SHELXD. Acta Crystallogr. 58, 1772-1779 (2002).
27. Terwilliger, T. C. Maximum-likelihood density modification. Acta Crystallogr. 56, 965-972 (2000).
28. Bransteitter, R., Pham, P., Scharff, M. D. & Goodman, M. F. Activation-induced cytidine deaminase deaminates deoxycytidine on single-stranded DNA but requires the action of RNase. Proc. Natl Acad. Sci. USA 100, 4102-4107 (2003).